{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:44:19Z","timestamp":1789879459551,"version":"4.0.1"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008789","name":"Department of Science and Technology, Government of West Bengal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jns.2016.01.008","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T03:35:17Z","timestamp":1452224117000},"page":"256-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"special_numbering":"C","title":["Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products"],"prefix":"10.1016","volume":"361","author":[{"given":"Manika","family":"Awasthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veda P.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upendra N.","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2016.01.008_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuron.2008.06.018","article-title":"Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta","volume":"59","author":"Adlard","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2016.01.008_bb0010","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","article-title":"Phase II study targeting amyloid-\u03b2 with 3APS in mild-to-moderate Alzheimer disease","volume":"67","author":"Aisen","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.01.008_bb0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbr.2007.03.001","article-title":"A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta (25\u201335)","volume":"180","author":"Alkam","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2014.02.001","article-title":"Alzheimer's disease facts and figures","volume":"10","author":"Alzheimer's Association","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of Alzheimer's disease: past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jns.2016.01.008_bb0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jnutbio.2008.03.002","article-title":"Protective effect of quercetin in primary neurons against Abeta (1\u201342): relevance to Alzheimer's disease","volume":"20","author":"Ansari","year":"2009","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jns.2016.01.008_bb0040","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.fct.2010.02.035","article-title":"In vitro antioxidant activities and an investigation of neuroprotection by six Salvia species from Iran: a comparative study","volume":"48","author":"Asadi","year":"2010","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.jns.2016.01.008_bb0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ng1197-263","article-title":"Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition","volume":"17","author":"Bales","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jns.2016.01.008_bb0050","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer's disease","volume":"377","author":"Ballard","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2016.01.008_bb0055","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2016.01.008_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.21623","article-title":"A \u03b3-secretase inhibitor decreases amyloid-\u03b2 production in the central nervous system","volume":"66","author":"Bateman","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0065","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2016.01.008_bb0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0075","doi-asserted-by":"crossref","first-page":"E4502","DOI":"10.1073\/pnas.1317918110","article-title":"Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease","volume":"110","author":"Benzinger","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2016.01.008_bb0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/13506120500106958","article-title":"Neurotoxic protein oligomers: what you see is not always what you get","volume":"12","author":"Bitan","year":"2005","journal-title":"Amyloid"},{"key":"10.1016\/j.jns.2016.01.008_bb0085","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer's disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0090","first-page":"30","article-title":"Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: rationale and treatment approach of the AMBAR (Alzheimer Management by Albumin Replacement) study","volume":"9","author":"Boada","year":"2014","journal-title":"Neurologia"},{"key":"10.1016\/j.jns.2016.01.008_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1212\/WNL.53.2.321","article-title":"APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the cache county study","volume":"53","author":"Breitner","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.01.008_bb0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/07388551.2011.596804","article-title":"Rosmarinic acid and its derivatives: biotechnology and applications","volume":"32","author":"Bulgakov","year":"2012","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.jns.2016.01.008_bb0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.wad.0000201847.29836.a5","article-title":"Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date","volume":"20","author":"Bullock","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jns.2016.01.008_bb0115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0006-8993(96)01262-0","article-title":"Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, Abeta1\u201342, in differentiated PC12 cells","volume":"746","author":"Burdick","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e318279bcfa","article-title":"Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease","volume":"36","author":"Burstein","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2016.01.008_bb0125","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1073\/pnas.90.5.2092","article-title":"Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells","volume":"90","author":"Busciglio","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2016.01.008_bb0130","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.8073293","article-title":"Rapid induction of Alzheimer A\u03b2 amyloid formation by zinc","volume":"265","author":"Bush","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jns.2016.01.008_bb0135","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1371\/journal.pone.0031424","article-title":"Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila","volume":"7","author":"Caesar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2016.01.008_bb0140","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1471-4159.2011.07225.x","article-title":"Amyloid-beta oligomers increase the localization of prion protein at the cell surface","volume":"117","author":"Caetano","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2016.01.008_bb0145","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1529\/biophysj.105.068726","article-title":"Amyloid fibril formation can proceed from different conformations of a partially unfolded protein","volume":"89","author":"Calamai","year":"2005","journal-title":"Biophys. J."},{"key":"10.1016\/j.jns.2016.01.008_bb0150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/bbrc.1995.2103","article-title":"Platelets are the primary source of amyloid beta-peptide in human blood","volume":"213","author":"Chen","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jns.2016.01.008_bb0155","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper\u2013zinc chelator markedly and rapidly inhibits \u03b2-amyloid accumulation in Alzheimer's disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2016.01.008_bb0160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14656566.2011.520702","article-title":"Current perspectives on pharmacotherapy of Alzheimer's disease","volume":"12","author":"Chopra","year":"2011","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2016.01.008_bb0165","first-page":"1","article-title":"Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"13","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0170","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1023\/A:1021942109490","article-title":"Effects of beta-amyloid-(25\u201335) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor","volume":"22","author":"Cowburn","year":"1997","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0175","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1021\/bi301137h","article-title":"BMS-708, 163 targets presenilin and lacks notch-sparing activity","volume":"51","author":"Crump","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.jns.2016.01.008_bb0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/NEN.0b013e318217a118","article-title":"Brain oligomeric \u03b2-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein\/tau transgenic mice","volume":"70","author":"Darocha-Souto","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.expneurol.2009.08.032","article-title":"Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention","volume":"223","author":"DaSilva","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0190","first-page":"1","article-title":"NIH state-of-the-science conference statement: preventing Alzheimer's disease and cognitive decline","volume":"27","author":"Daviglus","year":"2010","journal-title":"NIH Consens. State Sci. Statements"},{"key":"10.1016\/j.jns.2016.01.008_bb0195","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm890","article-title":"RAGE mediates amyloid-beta peptide transport across the blood\u2013brain barrier and accumulation in brain","volume":"9","author":"Deane","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2016.01.008_bb0200","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/j.1471-4159.2010.07058.x","article-title":"N-Methyl-d-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-beta peptide oligomers","volume":"115","author":"Decker","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2016.01.008_bb0205","first-page":"255","article-title":"Clinical trials of EHT0202, a neuroprotective and procognitive alpha-secretase","volume":"5","author":"Desire","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2016.01.008_bb0215","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1016\/j.neurobiolaging.2012.02.016","article-title":"Berberine ameliorates \u03b2-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model","volume":"33","author":"Durairajan","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2016.01.008_bb0220","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/14756366.2011.629197","article-title":"\u03b2-secretase inhibitory activity of phenolic acid conjugated chitooligosaccharides","volume":"28","author":"Eom","year":"2012","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.jns.2016.01.008_bb0225","doi-asserted-by":"crossref","first-page":"11141","DOI":"10.1073\/pnas.0403921101","article-title":"Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice","volume":"101","author":"Etcheberrigaray","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2016.01.008_bb0230","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.01.008_bb0235","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","article-title":"Phase 2 safety trial targeting amyloid-\u03b2 production with a \u03b3-secretase inhibitor in Alzheimer disease","volume":"65","author":"Fleisher","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0240","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1474-4422(12)70227-2","article-title":"Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross sectional study","volume":"11","author":"Fleisher","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","article-title":"Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence","volume":"27","author":"Freiherr","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2016.01.008_bb0250","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.neuint.2012.08.012","article-title":"The binding of resveratrol to monomer and fibril amyloid beta","volume":"61","author":"Ge","year":"2012","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jns.2016.01.008_bb0255","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0260","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jns.2016.01.008_bb0265","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jalz.2009.04.287","article-title":"NIC5-15 as a treatment for Alzheimer's: safety, pharmacokinetics and clinical variables","volume":"5","author":"Grossman","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0270","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003495-200161010-00005","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume":"61","author":"Grutzendler","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.jns.2016.01.008_bb0275","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.286.5441.916","article-title":"The presenilins in Alzheimer's disease-proteolysis holds the key","volume":"286","author":"Haass","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jns.2016.01.008_bb0280","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1523\/JNEUROSCI.11-12-03783.1991","article-title":"Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion","volume":"11","author":"Haass","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0285","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/359322a0","article-title":"Amyloid beta-peptide is produced by cultured cells during normal metabolism","volume":"359","author":"Haass","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jns.2016.01.008_bb0290","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","article-title":"Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives","volume":"9","author":"Hampel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2016.01.008_bb0295","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3346\/jkms.2014.29.7.886","article-title":"Primary prevention of Alzheimer's disease: is it an attainable goal?","volume":"29","author":"Han","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.jns.2016.01.008_bb0300","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/1565","article-title":"Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau","volume":"1","author":"Hardy","year":"1998","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0305","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jns.2016.01.008_bb0310","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/14656560903044982","article-title":"Development of semagacestat (LY450139), a functional \u03b3-secretase inhibitor, for the treatment of Alzheimer's disease","volume":"10","author":"Henley","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2016.01.008_bb0315","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1042\/bj3430419","article-title":"Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer \u03b2-amyloid fibril formation","volume":"343","author":"Howlett","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.jns.2016.01.008_bb0320","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5\u2032-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jns.2016.01.008_bb0325","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/156802608783334015","article-title":"Therapeutic potential of \u03b3-secretase inhibitors and modulators","volume":"8","author":"Imbimbo","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jns.2016.01.008_bb0330","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","article-title":"Why did tarenflurbil fail in Alzheimer's disease?","volume":"17","author":"Imbimbo","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0335","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/WAD.0b013e3182622ace","article-title":"Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects","volume":"27","author":"Imbimbo","year":"2012","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jns.2016.01.008_bb0340","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1523\/JNEUROSCI.22-06-02246.2002","article-title":"Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice","volume":"22","author":"Jantzen","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0345","first-page":"22","article-title":"Potential therapeutic strategies for Alzheimer's disease targeting or beyond \u03b2-amyloid: insights from clinical trials","author":"Jia","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.jns.2016.01.008_bb0350","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.lfs.2011.09.023","article-title":"Quercetin and rutin exhibit anti amyloidogenic and fibril disaggregating effects in vitro and potent antioxidant activity in APPswe cells","volume":"89","author":"Jim\u00e9nez-Aliaga","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.jns.2016.01.008_bb0355","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1474-4422(08)70169-8","article-title":"Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors","volume":"7","author":"Kalaria","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11010-009-0284-1","article-title":"Chitosan prevents oxidative stress-induced amyloid beta formation and cytotoxicity in NT2 neurons: involvement of transcription factors Nrf2 and NF-kappaB","volume":"337","author":"Khodagholi","year":"2010","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jns.2016.01.008_bb0365","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nm1234","article-title":"Amyloid \u03b2 protein immunotherapy neutralizes A\u03b2 oligomers that disrupt synaptic plasticity in vivo","volume":"11","author":"Klyubin","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2016.01.008_bb0370","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neurobiolaging.2007.01.002","article-title":"BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease","volume":"29","author":"Kobayashi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2016.01.008_bb0375","first-page":"405","article-title":"The beta-amyloid cascade hypothesis: a sequence of events leading to neurodegeneration in Alzheimer's disease","volume":"38","author":"Kowalska","year":"2004","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.jns.2016.01.008_bb0380","doi-asserted-by":"crossref","first-page":"548380","DOI":"10.4061\/2011\/548380","article-title":"Mechanisms of amyloid-beta peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins","volume":"2011","author":"Lai","year":"2010","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0385","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jalz.2012.05.237","article-title":"First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing","volume":"8","author":"Lai","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0390","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e31827db49b","article-title":"Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study","volume":"36","author":"Landen","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2016.01.008_bb0395","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nurt.2008.05.003","article-title":"PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease","volume":"5","author":"Landreth","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2016.01.008_bb0400","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt246","article-title":"Perspectives on future Alzheimer therapies: amyloid-\u03b2 protofibrils-a new target for immunotherapy with BAN2401 in Alzheimer's disease","volume":"6","author":"Lannfelt","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jns.2016.01.008_bb0410","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jnutbio.2012.06.011","article-title":"Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its antineuroinflammatory properties","volume":"24","author":"Lee","year":"2012","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jns.2016.01.008_bb0415","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1326-8-36","article-title":"Immunotherapy for Alzheimer's disease: hoops and hurdles","volume":"8","author":"Lemere","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jns.2016.01.008_bb0420","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","article-title":"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP","volume":"293","author":"Lewis","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jns.2016.01.008_bb0425","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/138161212798919075","article-title":"Resveratrol, a neuroprotective supplement for Alzheimer's disease","volume":"18","author":"Li","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jns.2016.01.008_bb0430","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/jnr.20315","article-title":"(\u2212)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury","volume":"78","author":"Li","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0435","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3390\/molecules16032084","article-title":"Luteolin isolated from the medicinal plant Elsholtzia rugulosa (Labiatae) prevents copper-mediated toxicity in \u03b2-amyloid precursor protein Swedish mutation overexpressing SH-SY5Y cells","volume":"16","author":"Liu","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.jns.2016.01.008_bb0440","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.med.57.121304.131442","article-title":"Current pharmacotherapy for Alzheimer's disease","volume":"57","author":"Lleo","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jns.2016.01.008_bb0445","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.neurobiolaging.2010.04.036","article-title":"Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment","volume":"31","author":"Lorenzi","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2016.01.008_bb0450","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","article-title":"Mice deficient in BACE1, the Alzheimer's \u03b2-secretase, have normal phenotype and abolished \u03b2-amyloid generation","volume":"4","author":"Luo","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0455","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/sj.bjc.6601321","article-title":"A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer","volume":"89","author":"Madhusudan","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jns.2016.01.008_bb0460","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1074-7613(03)00325-X","article-title":"Notch and the immune system","volume":"19","author":"Maillard","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.jns.2016.01.008_bb0465","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2008-15207","article-title":"Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG)","volume":"15","author":"Mandel","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0470","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0475","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","article-title":"Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing","volume":"106","author":"Marcade","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2016.01.008_bb0480","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.109.152975","article-title":"Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein \u03b3-secretase for the treatment of Alzheimer's disease","volume":"331","author":"Martone","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jns.2016.01.008_bb0485","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2016.01.008_bb0490","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","article-title":"The potent BACE1 inhibitor LY2886721 elicits robust central A\u03b2 pharmacodynamic responses in mice, dogs, and humans","volume":"35","author":"May","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0495","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.coi.2009.05.023","article-title":"Immuno-senescence: what does it mean to health outcomes in older adults?","volume":"21","author":"McElhaney","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jns.2016.01.008_bb0500","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0505","doi-asserted-by":"crossref","first-page":"18495","DOI":"10.1074\/jbc.M906994199","article-title":"Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Abeta-induced toxicity","volume":"275","author":"McLaurin","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2016.01.008_bb0510","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0304-3940(01)01754-2","article-title":"Amyloid beta protein 1\u201340 and 1\u201342 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease","volume":"304","author":"Mehta","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jns.2016.01.008_bb0515","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.337.6096.790","article-title":"Stopping Alzheimer's before it starts","volume":"337","author":"Miller","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jns.2016.01.008_bb0520","doi-asserted-by":"crossref","first-page":"127984","DOI":"10.4061\/2011\/127984","article-title":"A\u03b2 internalization by neurons and glia","volume":"2011","author":"Mohamed","year":"2011","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0525","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s004060050027","article-title":"The case described by Alois Alzheimer in 1911","volume":"248","author":"Moller","year":"1998","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0530","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1742-4933-10-18","article-title":"Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets?","volume":"10","author":"Moreth","year":"2013","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.jns.2016.01.008_bb0535","first-page":"120","article-title":"Anti-cholinergic alkaloids as potential therapeutic agents for Alzheimer's disease: an in silico approach","volume":"50","author":"Naaz","year":"2013","journal-title":"Ind. J. Biochem. Biophys."},{"key":"10.1016\/j.jns.2016.01.008_bb0540","doi-asserted-by":"crossref","first-page":"13827","DOI":"10.1074\/jbc.M110.199885","article-title":"Nature of the amyloid-\u03b2 monomer and the monomer\u2013oligomer equilibrium","volume":"286","author":"Nag","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2016.01.008_bb0545","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.jns.2016.01.008_bb0550","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ng1099","article-title":"Notch1 functions as a tumor suppressor in mouse skin","volume":"33","author":"Nicolas","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jns.2016.01.008_bb0555","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","article-title":"Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome","volume":"43","author":"Oddo","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2016.01.008_bb0560","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0896-6273(03)00810-9","article-title":"BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease","volume":"41","author":"Ohno","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2016.01.008_bb0565","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1523\/JNEUROSCI.6417-10.2011","article-title":"Amyloid \u03b2-induced death in neurons involves glial and neuronal hemichannels","volume":"31","author":"Orellana","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0570","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.01.008_bb0575","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5507\/bp.2011.036","article-title":"Cholinesterases, a target of pharmacology and toxicology","volume":"155","author":"Pohanka","year":"2011","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/j.jns.2016.01.008_bb0580","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4161\/pri.6.1.18317","article-title":"Therapeutic effect of CHF5074, a new \u03b3-secretase modulator, in a mouse model of scrapie","volume":"6","author":"Poli","year":"2012","journal-title":"Prion"},{"key":"10.1016\/j.jns.2016.01.008_bb0585","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ana.22105","article-title":"Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease","volume":"68","author":"Quiroz","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0590","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/jnnp-2012-303299","article-title":"Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers","volume":"84","author":"Quiroz","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2016.01.008_bb0595","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1006\/nbdi.2001.0422","article-title":"A cholesterol-lowering drug reduces \u03b2-amyloid pathology in a transgenic mouse model of Alzheimer's disease","volume":"8","author":"Refolo","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0600","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-2011-0059","article-title":"Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments","volume":"26","author":"Reiman","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0605","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","article-title":"Epidemiology of Alzheimer disease","volume":"7","author":"Reitz","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0610","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2016.01.008_bb0615","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/JAD-2006-10408","article-title":"Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid","volume":"10","author":"Riekse","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0620","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0197-4580(96)00115-7","article-title":"Inflammation and Alzheimer's disease pathogenesis","volume":"17","author":"Rogers","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2016.01.008_bb0625","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1326-7-61","article-title":"Modulation of \u03b3-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice","volume":"7","author":"Rogers","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jns.2016.01.008_bb0630","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/j.1471-4159.1993.tb09834.x","article-title":"Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue","volume":"61","author":"Roher","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2016.01.008_bb0635","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3233\/JAD-2009-1118","article-title":"Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing","volume":"17","author":"Ryan","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0640","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/WAD.0b013e318204b550","article-title":"PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease","volume":"25","author":"Sabbagh","year":"2011","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jns.2016.01.008_bb0645","doi-asserted-by":"crossref","first-page":"600","DOI":"10.33786\/JCPR.2012.v02i03.015","article-title":"Computational approaches for drug design and discovery process","volume":"2","author":"Sahoo","year":"2012","journal-title":"Curr. Pharma Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0650","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.01.008_bb0655","doi-asserted-by":"crossref","first-page":"15595","DOI":"10.1073\/pnas.1001740107","article-title":"Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering","volume":"107","author":"Sandberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2016.01.008_bb0660","doi-asserted-by":"crossref","first-page":"e55847","DOI":"10.1371\/journal.pone.0055847","article-title":"The pathogenic A\u03b243 is enriched in familial and sporadic Alzheimer disease","volume":"8","author":"Sandebring","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2016.01.008_bb0665","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jalz.2010.05.437","article-title":"A novel multivalent Abeta peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of abeta peptide species","volume":"6","author":"Savage","year":"2010","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0670","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jns.2016.01.008_bb0675","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0167-4889(00)00087-2","article-title":"The biology of the receptor for advanced glycation end products and its ligands","volume":"1498","author":"Schmidt","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jns.2016.01.008_bb0680","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","article-title":"Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing","volume":"13","author":"Schneeberger","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.jns.2016.01.008_bb0685","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11064-011-0612-1","article-title":"The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3\u03b2 pathway mediates bilobalide-induced reduction in amyloid \u03b2-peptide","volume":"37","author":"Shi","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0690","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2202-14-44","article-title":"Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice","volume":"14","author":"Sivilia","year":"2013","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0695","first-page":"699","article-title":"Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts","volume":"38","author":"Smith","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0700","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1749-6632.2000.tb06384.x","article-title":"Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations","volume":"903","author":"Sparks","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2016.01.008_bb0705","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0710","doi-asserted-by":"crossref","first-page":"12443","DOI":"10.1073\/pnas.0505690102","article-title":"Direct regulation of intestinal fate by Notch","volume":"102","author":"Stanger","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2016.01.008_bb0715","doi-asserted-by":"crossref","first-page":"7177","DOI":"10.1016\/j.bmc.2008.06.045","article-title":"Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation","volume":"16","author":"Sun","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jns.2016.01.008_bb0720","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0065-3233(08)60320-4","article-title":"The structure of amyloid fibrils by electron microscopy and X-ray diffraction","volume":"50","author":"Sunde","year":"1997","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.jns.2016.01.008_bb0725","doi-asserted-by":"crossref","first-page":"20822","DOI":"10.1073\/pnas.1011689107","article-title":"Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits","volume":"107","author":"Tamayev","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2016.01.008_bb0730","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jalz.2009.05.177","article-title":"Beta-secretase as target for amyloid-reduction therapy","volume":"5","author":"Tang","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0735","first-page":"144","article-title":"Evaluation of effectiveness of herbal medication in cancer care: a review study","volume":"5","author":"Tavakoli","year":"2012","journal-title":"Iran J. Cancer Prev."},{"key":"10.1016\/j.jns.2016.01.008_bb0740","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13607863.2011.583632","article-title":"Risk factors of dementia in north India: a case\u2013control study","volume":"16","author":"Tripathi","year":"2012","journal-title":"Aging Ment. Health"},{"key":"10.1016\/j.jns.2016.01.008_bb0745","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ng0594-74","article-title":"Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease","volume":"7","author":"van Duijn","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jns.2016.01.008_bb0750","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1472-8206.2008.00578.x","article-title":"Current and future therapy in Alzheimer's disease","volume":"22","author":"van Marum","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2016.01.008_bb0755","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","article-title":"BACE1 inhibitor drugs in clinical trials for Alzheimer's disease","volume":"6","author":"Vassar","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jns.2016.01.008_bb0760","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4103\/2231-4040.104709","article-title":"Natural products derived from plants as a source of drugs","volume":"3","author":"Veeresham","year":"2012","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0765","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/nbdi.2001.0470","article-title":"Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains","volume":"9","author":"Wahrle","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0770","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1021\/bi001048s","article-title":"The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain","volume":"39","author":"Walsh","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.jns.2016.01.008_bb0775","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/npp.2010.245","article-title":"Huperzine A activates Wnt\/\u03b2-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model","volume":"36","author":"Wang","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jns.2016.01.008_bb0780","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jalz.2005.06.228","article-title":"The developmentof NIC5-15, a natural anti-diabetic agent, in the treatment of Alzheimer's disease","volume":"1","author":"Wang","year":"2005","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0785","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","article-title":"Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jns.2016.01.008_bb0790","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/jnr.22775","article-title":"Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe\/PS1dE9 transgenic mice","volume":"90","author":"Wang","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0795","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic \u03b2A42 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jns.2016.01.008_bb0800","doi-asserted-by":"crossref","first-page":"P137","DOI":"10.1016\/j.jalz.2013.04.079","article-title":"Challenges in international clinical trials to delay early symptomatic Alzheimer's disease","volume":"9","author":"Welsh-Bohmer","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0805","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-2008-15404","article-title":"Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials","volume":"15","author":"Wilcock","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2016.01.008_bb0810","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1523\/JNEUROSCI.1339-09.2009","article-title":"Amyloid reduction by amyloid-\u03b2 vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease","volume":"29","author":"Wilcock","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0815","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1126\/science.1132341","article-title":"Control of peripheral nerve myelination by the \u03b2-secretase BACE1","volume":"314","author":"Willem","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jns.2016.01.008_bb0820","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jalz.2009.05.356","article-title":"Results of the first-in-man study with the active A\u03b2 immunotherapy CAD106 in Alzheimer patients","volume":"5","author":"Winblad","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2016.01.008_bb0825","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","article-title":"Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors","volume":"57","author":"Wolozin","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.01.008_bb0830","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1734-1140(11)70629-6","article-title":"Curcumin mediates presenilin-1 activity to reduce \u03b2-amyloid production in a model of Alzheimer's disease","volume":"63","author":"Xiong","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jns.2016.01.008_bb0835","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1523\/JNEUROSCI.23-20-07504.2003","article-title":"Anti-inflammatory drug therapy alters \u03b2-amyloid processing and deposition in an animal model of Alzheimer's disease","volume":"20","author":"Yan","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2016.01.008_bb0840","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/990107","article-title":"Membrane anchored aspartyl protease with Alzheimer's disease \u03b2-secretase activity","volume":"402","author":"Yan","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jns.2016.01.008_bb0845","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.brainres.2012.11.019","article-title":"Apigenin attenuates copper-mediated \u03b2-amyloid neurotoxicity through antioxidation, mitochondrion protection and MAPK signal inactivation in an AD cell model","volume":"1492","author":"Zhao","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.jns.2016.01.008_bb0850","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ptr.4728","article-title":"Hepatoprotection of berberine against hydrogen peroxide-induced apoptosis by upregulation of sirtuin 1","volume":"27","author":"Zhu","year":"2013","journal-title":"Phytother. Res."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16300065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16300065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:47:51Z","timestamp":1758383271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X16300065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":170,"alternative-id":["S0022510X16300065"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.01.008","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}